Corcept Therapeutics (CORT) Raw Materials (2012 - 2024)

Corcept Therapeutics (CORT) reported Raw Materials of $704000.0 for Q1 2024, down 58.22% sequentially from $1.7 million in Q4 2020.

Corcept Therapeutics (CORT) Raw Materials (2012 - 2024) Analysis & Trends

Corcept Therapeutics (CORT) has 10 years of Raw Materials data on file, last reported at $704000.0 in Q1 2024.

For the quarter ending Q1 2024, Raw Materials changed N/A year-over-year to $704000.0; the trailing twelve-month figure through Mar 2024 stood at $704000.0 (changed N/A YoY), and the FY2020 full-year result was $1.7 million, up 21.31% from the prior year.
Raw Materials eased to $704000.0 in Q1 2024, from $1.7 million in the prior quarter.
In the past five years, Raw Materials ranged from a high of $1.7 million in Q4 2020 to a low of $704000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Corcept Therapeutics	9.99 Bn	9.65 Bn	162.02 Mn

Download Data